Pharmacogenetics - Back to reality - Andrew Owen, BSS, MSC, PhD, FSB

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

The ‘Back Side’ of Compartments - Saye Khoo, MD, PhD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Back-terial co-infections - Mohammed Lamorde, FRCP, PhD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Specific Complex Interactions (mechanic presentation) - David Burger, PharmD, PhD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine after Co-administration with Viekirax or Viekira Pak - Dwaipayan Mukherjee, PhD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Backing up clinical data with modelling - Marco Siccardi, PhD

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines - Dr. Leah Jimmerson

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration - Dr. Susan Ford

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin - Dr. Christine MacBrayne

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - Dr. Nancy Kim

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1) - Dr. Jennifer King

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters - Dr. Timothy Eley

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving - Dr. Jeff de Wet

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects - Dr. Hwa-Ping Feng

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions - Dr. Brian Kirby

International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016

(Abstract) Antiviral Activity of Tenofovir Alafenamide (TAF) against HIV-1 Subtypes and Emergence of K65R | Dr. C. Callebaut

European Meeting on HIV & Hepatitis 2016

(Abstract) Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death | Dr. A. Battisti

European Meeting on HIV & Hepatitis 2016

(Abstract) Clinical impact of vaccine-escape HBsAg mutants in HBV-infected patients: high rate of atypical serological profiles and increased level of viremia and transaminases | Dr. R. Salpini

European Meeting on HIV & Hepatitis 2016

(Abstract) HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression | Dr. L. Colagrossi

European Meeting on HIV & Hepatitis 2016

Community perspective | Rebekah Webb

European Meeting on HIV & Hepatitis 2016

Roadblocks to implementation | Pep Coll, MD

European Meeting on HIV & Hepatitis 2016

Maintenance Therapy - What is the scientific/ virological rational | Charles Boucher, MD, PhD

European Meeting on HIV & Hepatitis 2016

HIV attachment Inhibitors - Educational lecture in collaboration with ESAR | Thomas Klimkait, MD

European Meeting on HIV & Hepatitis 2016

PI remain important options for first line | Linos Vandekerckhove, MD, PhD

European Meeting on HIV & Hepatitis 2016